Home › Compare › STUPF vs ABBV
STUPF yields 3039.51% · ABBV yields 3.06%● Live data
📍 STUPF pulled ahead of the other in Year 1
Combined, STUPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STUPF + ABBV for your $10,000?
Straightup Resources Inc. engages in the acquisition and exploration of mineral properties in Canada. It holds a 100% interest in the Ferdinand Gold Project that comprise 17 contiguous mining claims covering an area of 7,143 hectares located in the Confederation-Uchi greenstone belt, as well as holds 100% undivided interest in Ranger/Otter Project located in Red Lake, Ontario. The company also holds an option to acquire a 100% interest in the Belanger Project comprising the RLX North, RLX South, and Belanger properties located in the District of Red Lake, Ontario; an option to acquire 100% interest Bear Head Gold Project, which comprise 31 mining claims totaling 1,944 hectares located in Ontario, Canada; and acquired 100% interest in West Cat Mine Project located in Nevada. Straightup Resources Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Full STUPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.